Amicus advances late-stage study of SD-101 in rare genetic skin disorder, analysis plan completed for primary endpoints, top-line data expected next quarter; shares ahead 6% premarket

|About: Amicus Therapeutics, Inc. (FOLD)|By:, SA News Editor

Amicus Therapeutics (NASDAQ:FOLD) is up 6% premarket on light volume in response to its announcement that it has completed its analysis plan for the co-primary endpoints in its Phase 3 ESSENCE study of topical medicine SD-101 for the treatment of epidermolysis bullosa, an inherited disorder characterized by skin blistering and lesions.

Top-line data should be available in Q3.

Subscribe for full text news in your inbox